Literature DB >> 17651703

Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant.

Daniel A Johnson1, Emma J Grant, Colin D Ingram, Sarah E Gartside.   

Abstract

BACKGROUND: Selective serotonin reuptake inhibitor (SSRI) antidepressant drugs have a delayed onset and commonly produce an incomplete therapeutic response. The therapeutic actions of SSRIs are thought to depend on increased forebrain extracellular serotonin (5-HT), after desensitization of somatodendritic 5-HT(1A) autoreceptors. Here we determined whether concurrent glucocorticoid receptor (GR) blockade enhances these neurochemical responses to the SSRI fluoxetine.
METHODS: Male rats were treated (3, 7, or 14 days) with either fluoxetine (10 mg/kg IP) or vehicle once daily, in combination with either a GR antagonist (Org 34850 15 mg/kg SC or Org 34517 25 mg/kg SC) or vehicle twice daily. After treatment, 5-HT in the medial prefrontal cortex was measured by microdialysis.
RESULTS: Chronic fluoxetine treatment (14 days) raised basal 5-HT and also attenuated the fall in 5-HT after acute systemic administration of fluoxetine (10 mg/kg IP), indicating desensitization of 5-HT(1A) autoreceptors. Concurrent chronic administration (14 days) of Org 34850 or Org 34517 enhanced the fluoxetine-induced increase in basal 5-HT. Org 34850 also hastened the 5-HT(1A) autoreceptor desensitization induced by chronic fluoxetine treatment. Org 34850 alone (14 days) failed to alter basal 5-HT or 5-HT(1A) autoreceptor desensitization.
CONCLUSIONS: Antidepressant response is proposed to depend on 5-HT(1A) autoreceptor desensitization and elevation of forebrain 5-HT. These data suggest adjunctive GR antagonists might both hasten and enhance antidepressant responses to SSRIs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17651703     DOI: 10.1016/j.biopsych.2007.05.003

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  Dorsal raphé nucleus glucocorticoid receptors inhibit tph2 gene expression in male C57BL/6J mice.

Authors:  Melanie Y Vincent; Nina C Donner; David G Smith; Christopher A Lowry; Lauren Jacobson
Journal:  Neurosci Lett       Date:  2017-11-22       Impact factor: 3.046

2.  Repeated subcutaneous administration of PT150 has dose-dependent effects on sign tracking in male Japanese quail.

Authors:  Beth Ann Rice; Meredith A Saunders; Julia E Jagielo-Miller; Mark A Prendergast; Chana K Akins
Journal:  Exp Clin Psychopharmacol       Date:  2019-03-21       Impact factor: 3.157

Review 3.  Hormonal Treatments for Major Depressive Disorder: State of the Art.

Authors:  Jennifer B Dwyer; Awais Aftab; Rajiv Radhakrishnan; Alik Widge; Carolyn I Rodriguez; Linda L Carpenter; Charles B Nemeroff; William M McDonald; Ned H Kalin
Journal:  Am J Psychiatry       Date:  2020-05-27       Impact factor: 18.112

4.  Facilitation of serotonin signaling by SSRIs is attenuated by social isolation.

Authors:  Elyse C Dankoski; Kara L Agster; Megan E Fox; Sheryl S Moy; R Mark Wightman
Journal:  Neuropsychopharmacology       Date:  2014-07-01       Impact factor: 7.853

5.  A functional Tph2 C1473G polymorphism causes an anxiety phenotype via compensatory changes in the serotonergic system.

Authors:  Stefan M Berger; Tillmann Weber; Stephanie Perreau-Lenz; Miriam A Vogt; Sarah E Gartside; Christiane Maser-Gluth; Laurence Lanfumey; Peter Gass; Rainer Spanagel; Dusan Bartsch
Journal:  Neuropsychopharmacology       Date:  2012-04-11       Impact factor: 7.853

6.  Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder.

Authors:  Rose C Mantella; Meryl A Butters; Janet A Amico; Sati Mazumdar; Bruce L Rollman; Amy E Begley; Charles F Reynolds; Eric J Lenze
Journal:  Psychoneuroendocrinology       Date:  2008-04-14       Impact factor: 4.905

Review 7.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

8.  Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.

Authors:  Gerard Honig; Minke E Jongsma; Marieke C G van der Hart; Laurence H Tecott
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

9.  Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).

Authors:  R Hamish McAllister-Williams; Eleanor Smith; Ian M Anderson; Jane Barnes; Peter Gallagher; Heinz C R Grunze; Peter M Haddad; Allan O House; Tom Hughes; Adrian J Lloyd; Elaine M M McColl; Simon H S Pearce; Najma Siddiqi; Baxi Sinha; Chris Speed; I Nick Steen; June Wainright; Stuart Watson; Fiona H Winter; I Nicol Ferrier
Journal:  BMC Psychiatry       Date:  2013-08-03       Impact factor: 3.630

10.  Metyrapone in treatment-resistant depression.

Authors:  Paul David Sigalas; Himanshu Garg; Stuart Watson; Richard Hamish McAllister-Williams; I Nicol Ferrier
Journal:  Ther Adv Psychopharmacol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.